Rabies Drug Development Pipeline Study, H2 2018
Rabies Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Rabies pipeline products.
DISEASE OVERVIEW
Human rabies is rare but fatal disease causing 50,000 deaths annually. Lyssavirus virus belonging to the family of Rhabdoviridae spreads the disease, from animals to humans, primarily dogs. Rabies prevention cost in the US is estimated to be around $300 million, with most of the cost diverted to vaccinating dogs. Further, bats are also an important cause for spread of the rabies disease. In Europe, less than 10 cases are reported in Europe since 2011. However, in emerging markets, the prevalence is larger and worldwide, the market is estimated to be around $2.5 billion.
To gain from such large market scope and addressing the unmet demand for rabies infections, 16 companies are currently developing therapeutic compounds. Majority of the pipeline products are vaccines for prevention of rabies. Companies involved in the Rabies infection disease pipeline include%li%Cadila Pharmaceuticals Ltd, Celltrion Inc, Changchun Institute of Biological Products, Curevac AG, Exxell BIO Inc, Humabs BioMed, Indian Immunologicals Ltd, Molecular Targeting Technologies Inc, NanoViricides Inc, Prosetta Biosciences Inc, Sanofi Pasteur SA, Synermore Biologics Co Ltd, VBI Vaccines Inc, Vir Biotechnology Inc, Yisheng Biopharma Co Ltd and Zydus Cadila.
REPORT DESCRIPTION
The Rabies pipeline guide presents complete overview of drugs currently being developed for Rabies. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rabies pipeline candidate.
Research and Development progress along with latest news related to each of the Rabies pipeline candidates is included.
Major companies participating in therapeutic development of Rabies are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Rabies from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rabies clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Rabies pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF RABIES PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Human rabies is rare but fatal disease causing 50,000 deaths annually. Lyssavirus virus belonging to the family of Rhabdoviridae spreads the disease, from animals to humans, primarily dogs. Rabies prevention cost in the US is estimated to be around $300 million, with most of the cost diverted to vaccinating dogs. Further, bats are also an important cause for spread of the rabies disease. In Europe, less than 10 cases are reported in Europe since 2011. However, in emerging markets, the prevalence is larger and worldwide, the market is estimated to be around $2.5 billion.
To gain from such large market scope and addressing the unmet demand for rabies infections, 16 companies are currently developing therapeutic compounds. Majority of the pipeline products are vaccines for prevention of rabies. Companies involved in the Rabies infection disease pipeline include%li%Cadila Pharmaceuticals Ltd, Celltrion Inc, Changchun Institute of Biological Products, Curevac AG, Exxell BIO Inc, Humabs BioMed, Indian Immunologicals Ltd, Molecular Targeting Technologies Inc, NanoViricides Inc, Prosetta Biosciences Inc, Sanofi Pasteur SA, Synermore Biologics Co Ltd, VBI Vaccines Inc, Vir Biotechnology Inc, Yisheng Biopharma Co Ltd and Zydus Cadila.
REPORT DESCRIPTION
The Rabies pipeline guide presents complete overview of drugs currently being developed for Rabies. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rabies pipeline candidate.
Research and Development progress along with latest news related to each of the Rabies pipeline candidates is included.
Major companies participating in therapeutic development of Rabies are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Rabies from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rabies clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Rabies pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF RABIES PIPELINE REPORT INCLUDES
- Panorama of Rabies pipeline markets including statistics on therapeutic drugs and companies involved
- Rabies Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Rabies pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Rabies pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Rabies pipeline therapeutics
- Get clear understanding of the entire Rabies pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Rabies pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Rabies Pipeline include-
Number of Companies with Rabies projects in pre-clinical Development-
Number of Companies with Rabies projects in Clinical Development-
Rabies Pipeline Companies based in Americas
Rabies Pipeline Companies based in Europe
Rabies Pipeline Companies based in Asia Pacific
Rabies Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Rabies Pipeline Agents in pre- clinical/Discovery stage of Development
Rabies Pipeline Agents in Clinical Development stage
Rabies Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rabies Pipeline agents
II. INSIGHTS INTO RABIES PIPELINE
1. Disease Overview
Introduction to Rabies
Symptoms and Causes of Rabies
Treatment or Prevention Options for Rabies
Other Details
2. Phase wise Pipeline Compounds
Rabies Pipeline- Pre- Clinical/Discovery stage Drugs
Rabies Pipeline- Phase 1 stage Drugs
Rabies Pipeline- Phase 2 stage Drugs
Rabies Pipeline- Phase 3 stage Drugs
Rabies Pipeline- Pre-Registration stage Drugs
3. Company wise Rabies Pipeline Compounds
4. Rabies Pipeline by Mechanism of Action
III. RABIES PIPELINE COMPOUND DETAILS
Rabies 3 dose vaccine
CT-P19
Rabies vaccine for human (Vero cell)
CV7202
CV8102
CV7201
(rabies/Ebola/Sudan/Marburg) tetravalent vaccine
RVC20
Rabies therapeutic monoclonal antibodies
Rabies mAb
RabiCide-I
Rabies vaccine
Rabies VRVg
SYN-023
rabies vaccine
RVC58
PIKA rabies vaccine
Rabimabs
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. RABIES PIPELINE COMPANY BRIEFS
Cadila Healthcare Ltd
Celltrion Inc
Curevac AG
Exxell BIO Inc
Humabs BioMed
Indian Immunologicals Ltd
Molecular Targeting Technologies Inc
NanoViricides Inc
Prosetta Biosciences Inc
Sanofi Pasteur SA
Synermore Biologics Co Ltd
VBI Vaccines Inc
Vir Biotechnology Inc
Yisheng Biopharma Co Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL RABIES PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Rabies Pipeline include-
Number of Companies with Rabies projects in pre-clinical Development-
Number of Companies with Rabies projects in Clinical Development-
Rabies Pipeline Companies based in Americas
Rabies Pipeline Companies based in Europe
Rabies Pipeline Companies based in Asia Pacific
Rabies Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Rabies Pipeline Agents in pre- clinical/Discovery stage of Development
Rabies Pipeline Agents in Clinical Development stage
Rabies Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Rabies Pipeline agents
II. INSIGHTS INTO RABIES PIPELINE
1. Disease Overview
Introduction to Rabies
Symptoms and Causes of Rabies
Treatment or Prevention Options for Rabies
Other Details
2. Phase wise Pipeline Compounds
Rabies Pipeline- Pre- Clinical/Discovery stage Drugs
Rabies Pipeline- Phase 1 stage Drugs
Rabies Pipeline- Phase 2 stage Drugs
Rabies Pipeline- Phase 3 stage Drugs
Rabies Pipeline- Pre-Registration stage Drugs
3. Company wise Rabies Pipeline Compounds
4. Rabies Pipeline by Mechanism of Action
III. RABIES PIPELINE COMPOUND DETAILS
Rabies 3 dose vaccine
CT-P19
Rabies vaccine for human (Vero cell)
CV7202
CV8102
CV7201
(rabies/Ebola/Sudan/Marburg) tetravalent vaccine
RVC20
Rabies therapeutic monoclonal antibodies
Rabies mAb
RabiCide-I
Rabies vaccine
Rabies VRVg
SYN-023
rabies vaccine
RVC58
PIKA rabies vaccine
Rabimabs
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. RABIES PIPELINE COMPANY BRIEFS
Cadila Healthcare Ltd
Celltrion Inc
Curevac AG
Exxell BIO Inc
Humabs BioMed
Indian Immunologicals Ltd
Molecular Targeting Technologies Inc
NanoViricides Inc
Prosetta Biosciences Inc
Sanofi Pasteur SA
Synermore Biologics Co Ltd
VBI Vaccines Inc
Vir Biotechnology Inc
Yisheng Biopharma Co Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL RABIES PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
